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Mutations within the gene encoding for the chloride ion channel
CFTR results in cystic fibrosis, the most common autosomal
recessive genetic disease in the Caucasian population. CFTR
regulates absorption and secretion mechanisms across intestinal
and airway mucosae. Although the intestinal phenotype can be
clinically handled, chronic infection and inflammation of the
lungs of CF patients remains the principal cause of morbidity
and mortality. The aim of this Research Topic is to provide to
the readers the most recent information available on “Strategies
to circumvent the CFTR defect in cystic fibrosis.” The Research
Topic is divided in three mains parts: the first part describes
the CFTR structure, processing and regulation of the normal
and mutant ion channels. Anna Patrick and Philip Thomas
(University of Texas Southwestern Medical Center, Dallas, USA)
review the molecular interactions leading to the complex folding
process of the CFTR protein and how essential steps are disrupted
in CFTR mutants. Soo Jung Kim and William Skach (Oregon
Health and Science University, Portland, USA) detail the timing
and coordination of specific folding steps of the native CFTR
in and across the ER membrane. Colleen Weiler and Mitchell
Drumm (Case Western Reserve University, Cleveland, USA)
broaden our views with genetic studies that have identified
variant genes implicated in the clinical manifestations of CF.
The second part of the Special topics discusses the molecular
targets to rescue CFTR processing. Rebecca Chanoux and Ronald
Rubenstein describe the current knowledge of the network of
cellular chaperones that facilitate the folding and trafficking of
CFTR to the plasma membrane. Then, a series of papers by the
groups of Teresinha Leal (Université Catholique de Louvain,
Brussels, Belgium) and John Hanrahan (McGill University,
Montreal, Canada) report interesting observations regarding the
potential of several inhibitors in correcting the CF phenotype
at the level of ion transport and inflammation. Luigi Maiuri
and collaborators (European Institute for Research in Cystic
Fibrosis, San Raffaele Scientific Institute, Milan, Italy) propose
to target the intracellular environment in order to reestablish
functional autophagy in CF epithelial cells. The third chapter is
dedicated to new molecules that have already been developed
or in development and able to rescue CFTR channel function
by targeting mutant CFTR at the mRNA (Michael Wilschanski,
Hadassah Hospitals- Hebrew University, Jerusalem, Israel)
and/or at the protein (Nicoletta Pedemonte and Luis Galietta,
Laboratorio di Genetica Molecolare, Istituto Giannina Gaslini
Genova, Italy) levels. Finally, the Special Topic is concluded by
an in-depth review by Christine Bear and collaborators (The
Hospital for Sick Children, Toronto, Canada). Importantly, the
gaps in our knowledge regarding the mechanism of action of
existing correctors, the unmet need to discover compounds
which restore proper CFTR structure and function in CF affected
tissues and new strategies for therapy development are discussed.
We are convinced that we achieved a very interesting Special
Topics thanks to the outstanding contributions of all authors.
We are especially grateful to the authors for having believed
in this project and accepted to share their knowledge. All
the manuscripts have been peer-reviewed and we would like to
thank the experts for helping us to reach an issue of high standard.
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